Treat-to-target in systemic lupus erythematosus: are we there yet?

Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period

(2016) Carmen V. Medina-Quiñones et al.   ARTHRITIS CARE & RESEARCH

Remission in SLE: closing in on the target

(2015) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Prolonged remission in Caucasian patients with SLE: prevalence and outcomes

(2015) Margherita Zen et al.   ANNALS OF THE RHEUMATIC DISEASES

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update

(2015) Michaela A Stoffer et al.   ANNALS OF THE RHEUMATIC DISEASES

Remission of proteinuria indicates good prognosis in patients with diffuse proliferative lupus nephritis

(2015) H S Koo et al.   LUPUS

A Randomized Trial of Intensive versus Standard Blood-Pressure Control

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of Long-Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro-Lupus Nephritis Cohort

(2015) Maria Dall'Era et al.   Arthritis & Rheumatology

Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up

(2014) Chi Chiu Mok et al.   ANNALS OF THE RHEUMATIC DISEASES

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

(2014) Ian N Bruce et al.   ANNALS OF THE RHEUMATIC DISEASES

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force

(2014) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Update on B-cell targeted therapies for systemic lupus erythematosus

(2014) Chi Chiu Mok   EXPERT OPINION ON BIOLOGICAL THERAPY

Emerging biological therapies for systemic lupus erythematosus

(2014) Chi Chiu Mok   EXPERT OPINION ON EMERGING DRUGS

Tocilizumab: A novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases

(2013) Rieke Alten et al.   ANNALS OF MEDICINE

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Acute myeloid leukaemia in adults

(2013) Felicetto Ferrara et al.   LANCET

Belimumab for Systemic Lupus Erythematosus

(2013) Bevra Hannahs Hahn   NEW ENGLAND JOURNAL OF MEDICINE

Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis

(2012) George K Bertsias et al.   ANNALS OF THE RHEUMATIC DISEASES

Update on emerging drug therapies for systemic lupus erythematosus

(2010) Chi Chiu Mok   EXPERT OPINION ON EMERGING DRUGS

Prolonged Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Frequency and Outcome

(2010) A. J. STEIMAN et al.   JOURNAL OF RHEUMATOLOGY

Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study

(2009) Jason W. Bauer et al.   ARTHRITIS AND RHEUMATISM

Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis

(2009) G. B. Appel et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial

(2009) Paolo Verdecchia et al.   LANCET

Prognostically distinct clinical patterns of systemic lupus erythematosus identified by cluster analysis

(2009) CH To et al.   LUPUS